MYC and diffuse large B-cell lymphoma: In conclusion, the results of the present study showed good prognoses, and suggest that the double expression of MYC and BCL2 did not influence the outcomes of localized PG-DLBCL patients treated with rituximab-containing chemotherapy with or without RT.